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ABSTRACT: Accumulating preclinical and clinical evidence suggests that calcification is one of the body’s primary responses to 
injury and a key pathological feature of cardiovascular disease. Calcification activity can now be imaged using 18F-NaF positron 
emission tomography (PET) in combination with either computed tomography or magnetic resonance. These techniques 
allow visualization of calcification activity and, therefore, provide different information to the established macroscopic calcium 
imaged with computed tomography. Indeed, 18F-NaF PET has been used to investigate a wide range of valvular conditions, 
including aortic stenosis, mitral annular calcification, and bioprosthetic valve disease, as well as vascular conditions, 
including abdominal aortic aneurysm disease, coronary, and carotid atherosclerosis, peripheral vascular disease, and erectile 
dysfunction. In this brief review, we will focus on how 18F-NaF PET has improved our pathophysiological understanding of 
cardiovascular calcification and how it can be used as a marker of vascular calcification, providing a useful tool that can be 
utilized in clinical trials investigating the prediction of both disease progression and clinical events. Finally, we will discuss how 
18F-NaF might be employed clinically to improve patient assessment and to guide decision-making.
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Calcification is a key feature of atherosclerosis, heart valve disease, and peripheral vascular disease, that is governed in a highly regulated manner with simi-
larities to skeletal bone formation. Computed tomography 
(CT), which detects large macroscopic deposits of cal-
cium, has until recently been the only available noninvasive 
imaging modality allowing visualization of this process.1 
However, imaging of this late stage means that the pro-
cesses leading to calcium formation have often resolved. 
There is, therefore, interest in imaging the earlier stages of 
microcalcification where the disease process is active and 
therapeutic intervention may be more effective.
Over the last 10 years, 18F-NaF positron emission 
tomography (PET) has emerged as a noninvasive quan-
titative imaging modality capable of imaging calcification 
activity in the vasculature. This has provided significant 
insight into the underlying pathophysiology of multiple 
different cardiovascular disease states and unique infor-
mation regarding disease activity that may prove clinically 
useful in the future. In this brief review, we will talk about 
how 18F-NaF PET works and how this novel approach has 
been used to investigate a range of valvular and vascular 
diseases including aortic stenosis, mitral annular calcifi-
cation (MAC), bioprosthetic valve degeneration, abdomi-
nal aortic aneurysm disease, erectile dysfunction, carotid 
atherosclerosis, and coronary artery disease (Figure 1).
UNDERSTANDING HOW 18F-NAF PET 
WORKS
CT is currently only able to identify macroscopic deposits 
of calcium with a diameter between 200 and 500 μm (CT 
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in areas of microcalcification (<50 μm) than macrocalcific 
deposits for a similar mass of calcium. Newly developing 
calcium, adjacent or remote from macrocalcific deposits 
will pass through this microcalcification stage so that 18F-
NaF effectively provides a marker of calcification activity, 
detecting new calcium formation beyond the resolution of 
CT.1,4 Initially used as bone tracer with increased uptake 
observed in conditions associated with high bone turn-
over and new bone formation,5–7 18F-NaF demonstrates 
favorable pharmacokinetic properties and has estab-
lished an excellent safety profile. Following intravenous 
injection, roughly 70% of 18F-NaF is plasma-based, with 
the remaining 30 % found in erythrocytes. Because of its 
small size and negligible protein binding, one hour after 
administration only ≈10% of the injected 18F-NaF dose 
remains in the blood (SUVmean [SD]=1.13 [0.05] in right 
atrium).8–10 The mechanism of 18F-NaF uptake in bone is 
well understood. First, it diffuses via the capillary network 
into the bone extracellular fluid, and then it exchanges 
with hydroxyl groups on exposed regions of hydroxyapa-
tite crystals on the bone surface to form fluorapatite.1 The 
intensity of the tracer uptake and as a result of the PET 
signal depends mainly on 2 factors: the bone blood flow 
and the surface area of exposed hydroxyapatite.1
Hydroxyapatite is also a key feature of vascular cal-
cification, with a growing literature demonstrating that 
similar mechanisms govern 18F-NaF PET binding in the 
cardiovascular system. However, here blood flow is likely 
to be fairly constant, so the surface area of hydroxyapatite 
appears to be the major factor affecting 18F-NaF uptake. 
Indeed 18F-NaF binding is highest in areas of microcalci-
fication compared with large macroscopic deposits due 
to the very high surface area of hydroxyapatite in these 
regions of powdery microcalcification.1,5,6,11 Unlike other 
PET tracers, 18F-NaF also demonstrates very low uptake 
in the myocardium, well below that observed even in the 
blood pool. This important characteristic facilitates clear 
visualization of regions of increased 18F-NaF uptake in 
areas of active calcification in the heart but also medi-
ates precise coregistration via alignment of the ventricu-
lar blood pools on PET and contrast CT.10,12–14
Validation of the cardiovascular 18F-NaF signal has 
now been provided in multiple independent studies. Using 
excised atherosclerotic plaque, Cocker et al15 demon-
strated the association between cardiovascular 18F-NaF 
PET uptake and the histological staining of hydroxyapa-
tite with Goldner trichome. Aikawa et al16 confirmed that 
18F-NaF binds predominantly to hydroxyapatite, whereas 
in the aortic valve, 18F-NaF has demonstrated a close 
association with areas of tissue with positive histochemi-
cal staining for alkaline phosphatase (r=0.65; P=0.04) 
and areas with positive immunohistochemical reactivity 
for osteocalcin (r=0.68; P=0.03).1,17 Irkle et al18 demon-
strated that 18F-NaF binding is increased in regions of 
microcalcification, rather than large macroscopic depos-
its. This is predominantly due to surface area effects and 
because much of the hydroxyapatite crystal is internal-
ized in the center of macroscopic deposit and, therefore, 
not available for 18F-NaF binding. Creager et al,1 con-
firmed that 18F-NaF binds to areas of microcalcification 
beyond the resolution of x-ray CT and that this binding 
was proportional to the surface area of hydroxyapatite 
in a controlled ex vivo model. Recently, Youn et al19 con-
firmed 18F-NaF binding to microcalcifications in the coro-
nary arteries as well as the carotids.
In effect, 18F-NaF-PET detects the surface area of 
hydroxyapatite crystal and, therefore, provides different 
information to x-ray CT, which detects tissue density. Put 
another way, 18F-NaF detects microcalcifications and 
areas of calcification activity, whereas CT detects estab-
lish macroscopic deposits of calcium. The difference infor-
mation provided by 18F-NaF PET compared with CT has 
now been demonstrated in multiple human studies in vivo 
across a range of different conditions, as discussed below. 
However, this observation was perhaps first described by 
Derlin et al20 in a study of 75 patients undergoing whole-
body 18F-NaF PET/CT. They demonstrated that in the 
aorta, carotids, and femoral arteries, only 12% of all cal-
cified plaques on CT demonstrated increased 18F-NaF 
uptake, whereas 75% of patients demonstrated increased 
18F-NaF uptake remote from calcified CT plaques.
VALVULAR APPLICATIONS
Aortic Stenosis and Bioprosthetic Valve 
Degeneration
Calcific aortic stenosis is the most common form of valve 
disease in the Western world and is set to become an 
increasing health burden with no available effective medi-
cal therapy.21 The only available treatment for patients that 
Nonstandard Abbreviations and Acronyms
CT computed tomography
PET positron emission tomography
PREFFIR  Prediction of Recurrent Events With 
18F-Fluoride
Highlights
• 18F-NaF positron emission tomography can be used 
to study calcification activity across the vasculature.
• It has been used to study (1) coronary artery dis-
ease, (2) carotid atherosclerosis, (3) abdominal 
aortic aneurysm disease, (4) aortic stenosis, (5) 
bioprosthetic valve degeneration and (6) erectile 
dysfunction.
• Ongoing clinical trials are evaluating its ability to 
predict both disease progression and clinical events 
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progress to severe symptomatic aortic stenosis remains 
surgical or transcatheter aortic valve replacement. There is, 
therefore, a pressing need to improve our pathophysiological 
understanding of the disease and to develop effective med-
ical therapies capable of slowing disease progression.22,23
Dweck et al24 recruited 121 patients with a range of 
calcific aortic valve disease who underwent both 18F-FDG 
(a marker of inflammation) and 18F-NaF PET/CT imag-
ing. 18F-NaF uptake activity was higher in aortic steno-
sis patients than controls and increased progressively 
with more advanced stages of aortic stenosis. Interest-
ingly increased 18F-FDG activity was also detected, but 
uptake values were lower than 18F-NaF and had only a 
mild association with disease severity. Particularly, in the 
more advanced stages of the disease, calcification, rather 
than inflammation, had a more predominant role in the 
disease progressionr25 On this basis, we think it should 
be the target of future therapeutic interventions, although 
acknowledge that other processes such as fibrosis also 
determine valve stiffening and progression. Once again, 
in aortic stenosis, 18F-NaF activity was observed in a 
different distribution to the presence of calcium on CT. 
Moreover, 18F-NaF PET predicted where new areas of 
calcium on CT would develop on repeat scans performed 
2 years later (Figure 2), consistent with it acting as marker 
of calcification activity and, therefore, providing powerful 
prediction of disease progression and future aortic valve 
replacement or cardiovascular mortality.26,27
Calcification also appears to have an important role in 
bioprosthetic valve degeneration, acting as a major patho-
logical contributor to both progressive bioprosthetic valve 
narrowing and leaflet tears.28 Cartlidge et al29 examined 
15 failed explanted bioprosthetic aortic valves using 18F-
NaF PET/CT. All valves demonstrated 18F-NaF leaflet 
uptake that correlated with microcalcific and macrocal-
cific deposits within the valve leaflets and colocalized with 
regions of tissue degradation, pannus, and thrombus on 
histology. Moreover, they examined 71 patients without 
known bioprosthetic valve dysfunction. Similar to the ex 
vivo findings, increased 18F-NaF uptake colocalized with 
areas of spotty calcification, noncalcific leaflet thickening 
(suggestive of thrombus), and pannus observed on the 
Figure 1. 18F-fluoride uptake in different disease states.
A, Patient with mild aortic valve stenosis and corresponding 18F-NaF uptake in areas of leaflet calcification (image derived from Dweck et al17), 
(B) patient with aortic valve degeneration and corresponding 18F-NaF uptake (reprinted from Cartlidge et al.29 Copyright ©2019, the Authors), 
(C) patient with abdominal aortic aneurysm (reprinted from Forsythe et al.42 Copyright ©2018, the Authors), (D) patient with recent myocardial 
infarction (reprinted from Joshi et al.34 Copyright ©2014, the Authors), (E) patient with recent transient ischemic attack and uptake in the 
culprit carotid artery (reprinted from Vesey et al.39 Copyright ©2014, the Authors), and (F) patient with erectile dysfunction and high penile 
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CT. Twenty-four patients with increased 18F-NaF uptake 
at baseline demonstrated clear evidence of deteriorat-
ing bioprosthesis function after 2 years, whereas patients 
without uptake displayed no change in valve function. Ten 
patients developed new bioprosthetic valve failure; all 10 
patients had increased 18F-NaF uptake at baseline.
Mitral Annular Calcification
MAC is a chronic process, the incidence of which is asso-
ciated with advanced age, atherosclerosis, and altered 
mineral metabolism. It can lead to mitral valve dysfunction 
and is associated with an increased risk of adverse car-
diovascular events; however, its pathophysiology remains 
incompletely understood.30,31 Massera et al32 investigated 
MAC using 18F-NaF and 18F-FDG positron emission 
tomography. The results were similar to those observed 
in aortic stenosis. Uptake of both tracers was higher in 
patients with MAC versus those with normal mitral valves 
and increased with disease severity. A strong correla-
tion was observed between the baseline CT-MAC score 
and mitral annular 18F-NaF activity (r=0.79, P<0.001), 
whereas a moderate correlation was observed with 18F-
FDG uptake (r=0.32, P=0.001). Similar to the aortic valve, 
areas of increased 18F-NaF activity on baseline imaging 
predicted where new regions of macroscopic calcium on 
CT would develop after 2 years. Indeed, there was a close 
association observed between baseline 18F-NaF and the 
change in CT calcium score (r=0.75, P<0.001), with 18F-
NaF again emerging as a marker of disease activity and 
predictor of disease progression in this condition.
VASCULAR APPLICATIONS
Coronary and Carotid Atherosclerosis
Dweck et al33 first described 18F-NaF uptake in the coro-
nary arteries as a novel marker of microcalcification activ-
ity in subjects with and without aortic valve disease. Again 
18F-NaF provided different information to CT. More than 
40 % of patients with high coronary artery calcium scores 
(>1000 Agatston Units) did not demonstrate increased 
18F-NaF uptake, signifying that 18F-NaF might be able to 
differentiate between active disease and advanced yet 
burnt out atheroma. Increased 18F-NaF uptake could be 
localized to individual coronary plaques and notably identi-
fied patients with both increased cardiac risk scores and a 
history of prior cardiovascular events. Joshi et al34 examined 
40 patients with stable angina and 40 patients presenting 
with type 1 myocardial infarction, who all underwent 18F-
NaF PET/CT. In the stable cohort, high tracer activity local-
ized to individual coronary plaques in ≈40 % of patients. 
Using intravascular ultrasound and CT, these plaques 
had multiple adverse, unstable characteristics, including 
Figure 2. 18F-NaF uptake predicts progression of aortic valve calcification and mitral annular calcification (MAC).
A, Baseline calcium score (left) of 2 patients with aortic sclerosis (top) and moderate aortic stenosis (bottom). Fused 18F-NaF positron 
emission tomography (PET)–computed tomography (CT) scans (middle) show fluoride uptake in red and yellow. Follow-up CT at 2 y (right) 
indicated new areas of macroscopic calcium on the repeat CT in a similar distribution to the PET activity (reprinted from Jenkins et al47 with 
permission. Copyright ©2015, the Journal of the American College of Cardiology). B, Baseline calcium score (left) of patients with mild, 
moderate, and severe MAC. Fused 18F-NAF PET-CT scans (middle) show fluoride uptake in red and yellow. Similar to the aortic valve the 
baseline PET predicts where new macroscopic calcium in the mitral valve will develop on follow-up CT at 2 y (right) (reprinted from Massera et 
al.44 Copyright ©2019, the Authors).D
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microcalcification, positive remodeling, and a large necrotic 
core. In a separate cohort of patients with carotid artery 
disease undergoing endarterectomy, increased 18F-NaF 
activity similarly colocalized to carotid plaques with histo-
logical adverse plaque features, including increased mac-
rophage accumulation, cell death, and calcification. Finally, 
in the myocardial infarction cohort, 37 out of 40 patients 
demonstrated increased 18F-NaF uptake at the exact site 
of the culprit coronary plaque responsible for the event. By 
comparison, 18F-FDG was not able to provide similar dis-
crimination of culprit coronary plaques.
Other studies have confirmed the localization of 
increased 18F-NaF to plaques with adverse characteristics 
including positive remodeling, low attenuation plaque (<30 
HU), spotty calcification, obstructive coronary stenosis, and 
plaque volumes >100 mm3 determined by a range of dif-
ferent approaches, including CT, intravascular ultrasound, 
optical coherent tomography, and histology.19,35–37 More 
recently 18F-NaF PET activity has been associated with 
increased pericoronary adipose tissue density: an emerg-
ing marking of coronary plaque inflammation.38
Outside the heart, Vesey et al39 examined 18F-NaF and 
18F-FDG uptake in the carotid arteries after transient isch-
emic attack or stroke. They recruited 26 patients following 
a recent cerebrovascular event. All individuals underwent 
PET/CT scanning using both tracers. 18F-NaF uptake was 
focal, readily identifiable, and localizable to plaque. The 
authors detected increased 18F-NaF within culprit lesions 
responsible for stroke compared with both the contralateral 
nonculprit carotid artery as well as arteries from patients 
with nonsymptomatic carotid disease. Similar discrimina-
tion was again not provided by 18F-FDG. In a smaller study 
of 9 patients, Quirce et al40 explored 18F-NaF and 18F-FDG 
uptake in patients with symptomatic carotid stenosis and 
showed again that 18F-NaF uptake appeared to be higher 
in the symptomatic carotid, whereas 18-FDG uptake was 
nondiscriminatory. Cocker et al41 examined 11 patients 
scheduled to have endarterectomy. They performed 18F-
NaF PET/ CT imaging of the carotid arteries <2 weeks 
before surgery and established greater 18F-NaF uptake in 
symptomatic versus nonsymptomatic plaque.
The retrospective identification of culprit plaque is 
only of limited clinical utility. More interesting is whether 
18F-NaF can prospectively identify patients at increased 
risk of myocardial infarction so that preventative thera-
pies might be institute to avoid such an event. The prog-
nostic role of 18F-NaF is currently being evaluated in an 
ongoing prospective multicenter trial: PREFFIR (Predic-
tion of Recurrent Events With 18F-Fluoride; https://www.
clinicaltrials.gov; Unique identifier: NCT02278211).
Abdominal Aortic Aneurysms, Peripheral Artery 
Disease, and Erectile Dysfunction
18F-NaF PET has also been also explored in patients with 
abdominal aortic aneurysm disease, peripheral vascular 
disease, and erectile dysfunction. In the SOFIA3 study, 
Forsythe et al42 first performed micro–PET-CT and his-
tological analysis of excised abdominal aortic aneurysm 
disease tissue, establishing once more that 18F-NaF 
acts as a marker of microcalcification activity. Then they 
investigated 18F-NaF PET-CT imaging in patients with 
abdominal aortic aneurysm disease and control subjects. 
Increased 18F-NaF uptake was observed in the aneu-
rysms compared with areas of nonaneurysmal aorta, 
providing important predictive information. Aneurysms in 
the highest 18F-NaF uptake tertile expanded 2.5× more 
rapidly than those in the lowest tertile. They were also 
nearly 3× as likely to experience abdominal aortic aneu-
rysm disease repair or rupture. On multivariable analysis, 
18F-NaF provided incremental prognostic information 
over conventional predictors of risk, including aneurysm 
size. Interestingly, CT calcium scoring was not predictive 
of either aneurysm expansion nor clinical events.
In peripheral vascular disease, Chowdhury et al43 per-
formed a prospective observational study of 50 patients 
with symptomatic peripheral arterial disease undergoing 
18F-FDG and 18F-NaF PET/CT of the superficial femoral 
artery before and 6 weeks after angioplasty. The investiga-
tors found that both tracers performed well in identifying 
patients who would develop restenosis within 12 months; 
indeed, there was clear separation of 18F-NaF activity in 
patients that did and did not go on to develop restenosis.
Finally, Nakahara et al44 investigated 18F-NaF uptake 
in the penile arteries of prostate cancer patients under-
going clinical PET scans. The investigators demonstrated 
that 18F-NaF uptake in the cavernous and dorsal penile 
arteries was associated with the both the presence of 
existing erectile dysfunction and the probability of its 
future development. Indeed, penile 18F-NaF activity was 
30% higher in patients with compared with patients with-
out erectile dysfunction.
Limitations
PET-CT has grown significantly over the last decade 
but still faces important challenges. Most notably is the 
expense of PET imaging, radiation exposure, and the rela-
tively limited availability of this imaging modality. These may 
limit its widespread clinical adoption, although we note the 
increasing use of PET in oncology. In addition, there are 
technical challenges. In particular, PET imaging of the heart 
is complicated by cardiac, respiratory, and gross patient 
motion and how this effects image quality, particularly in 
small structures, such as the coronary arteries. Several 
motion correction methods have been proposed, leading to 
novel image reconstruction techniques, and the develop-
ment of new software that can precisely read fused images. 
The first approach was to ECG-gate the images and only 
use PET data acquired in diastole when the heart is still 
(between 50% and 75% of the R-R interval).14 Although 
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ignores three-fourth of the total PET signal leading to 
increased noise. Doris et al45 used an alternative technique 
that modeled and then corrected for cardiac motion in the 
PET data using anatomy guided registration algorithm to 
preserve all of the PET data. Finally, Lassen et al,46 used an 
approach that corrected for cardiac, respiratory, and gross 
patient motion that in combination with background blood 
pool corrections markedly improved test-retest reproduc-
ibility of coronary 18F-NaF PET.
Clinical Trials
Although 18F-NaF PET has provided important patho-
physiological insights and emerged consistently as a 
marker of vascular injury and predictor of disease pro-
gression, further work is required to demonstrate the 
incremental clinical utility of this imaging technique 
and to justify its relatively high costs. This question is 
being addressed in multiple prospective studies. As dis-
cussed, the PRE18FFIR Study is a multicenter observa-
tional study that will follow ≈700 high-risk patients with 
coronary artery disease to determine whether baseline 
18F-NaF PET imaging can identify patients at increased 
risk of future myocardial infarction and disease progres-
sion. SALTIRE 2 (https://www.clinicaltrials.gov; Unique 
identifier: NCT02132036) will utilize 18F-NaF PET to 
determine if denosumab or bisphosphonate can reduce 
calcification activity and slow aortic stenosis progression 
in patients with mild and moderate aortic stenosis.
CONCLUSIONS
18F-NaF PET provides a marker of calcification 
activity across a range of cardiovascular conditions, 
providing potentially useful prediction of disease pro-
gression and clinical events. Although the technique 
has already provided some key pathophysiological 
insights and is being used as a surrogate efficacy end 
point in ongoing randomized clinical trials, large pro-
spective studies are required to examine whether it 
can provide incremental information to justify its more 
widespread clinical use.
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